<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149519">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01714388</url>
  </required_header>
  <id_info>
    <org_study_id>GUMed-Ow-004</org_study_id>
    <nct_id>NCT01714388</nct_id>
  </id_info>
  <brief_title>Vagotonic Effect of Remifentanil and Autonomic Nervous System Activity.</brief_title>
  <official_title>Vagotonic Effect of Remifentanil in Reference to Sympathetic or Parasympathetic Predominance of Autonomic Nervous System.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <authority>Poland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remifentanil (RMFNT) is a very short active opioid, used for analgesia during general
      anaesthesia and for analgosedation in intensive care units (ICU). Registration for
      anesthesia includes bolus dose and continuous infusion, in ICU only infusion regimen is
      allowed. PK/PD parameters of RMFNT results in rapid onset and offset of clinical effect,
      which makes this drug almost ideal in many situations. Unfortunately, its vagomimetic
      influence on cardiac activity may result in decrease of heart rate. It may be hypothesized
      that patients with parasympathetic predominance may be prone to more intense
      parasympaticomimetic effect of this opioid. An optimal method for assessment of autonomic
      nervous system activity and assessment of influence of RMFNT on that activity is Heart Rate
      Variability (HRV) analysis. Parasympathetic predominance is expressed as HF power and
      HF/(LF+HF) ratio in frequency domain and RMSSD, NN50, pNN50 in time domain. The aim of this
      study is to verify the hypothesis that patients with predominance of parasympathetic
      activity are more subject to vagomimetic effect of RMFNT. HRV based on 5 minutes ECG
      recorded before and after bolus dose of RMFNT will be analyzed. The occurrence of heart rate
      decrease will be than compared between patients with sympathetic and parasympathetic
      predominance measured prior to drug injection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Vagomimetic effect of RMFNT in reference to autonomic nervous system activity</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Autonomic Nervous Sytem Activity</condition>
  <condition>Inluence of Remifentanil on Autonomic Nervous System</condition>
  <arm_group>
    <arm_group_label>Remifentanil, Vagotonic response</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>1mcg/kg iv dose, followed by 5 minutes ECG recording</description>
    <arm_group_label>Remifentanil, Vagotonic response</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients ASA I-II status

          -  planned surgery under general anaesthesia

        Exclusion Criteria:

          -  known sensivity to remifentanil

          -  anticipated problems with tracheal intubation

          -  incresed risk of aspiration

          -  diabetic patients

          -  patients taking medications with known influence on autonomic nervous system
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena A. Wujtewicz, MD., PhD</last_name>
      <phone>48583493281</phone>
      <email>magwuj@gumed.edu.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 24, 2012</lastchanged_date>
  <firstreceived_date>October 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Gdansk</investigator_affiliation>
    <investigator_full_name>Radoslaw Owczuk</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>remifentanil</keyword>
  <keyword>heart rate</keyword>
  <keyword>autonomic nervous system</keyword>
  <keyword>heart rate variability</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
